NovaBay Pharmaceuticals, Inc.
NBY · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,781 | $10,455 | $14,404 | $10,204 |
| % Growth | -6.4% | -27.4% | 41.2% | – |
| Cost of Goods Sold | $3,300 | $4,371 | $6,623 | $3,689 |
| Gross Profit | $6,481 | $6,084 | $7,781 | $6,515 |
| % Margin | 66.3% | 58.2% | 54% | 63.8% |
| R&D Expenses | $42 | $34 | $174 | $44 |
| G&A Expenses | $7,379 | $5,447 | $7,489 | $7,240 |
| SG&A Expenses | $11,413 | $10,152 | $15,287 | $15,333 |
| Sales & Mktg Exp. | $4,034 | $4,705 | $7,798 | $8,093 |
| Other Operating Expenses | $865 | $0 | $6,737 | $0 |
| Operating Expenses | $12,320 | $10,186 | $22,198 | $15,377 |
| Operating Income | -$5,839 | -$4,102 | -$14,417 | -$8,862 |
| % Margin | -59.7% | -39.2% | -100.1% | -86.8% |
| Other Income/Exp. Net | -$1,371 | -$2,043 | $3,809 | $3,038 |
| Pre-Tax Income | -$7,210 | -$6,145 | -$10,608 | -$5,824 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,223 | -$9,640 | -$10,608 | -$5,824 |
| % Margin | -73.8% | -92.2% | -73.6% | -57.1% |
| EPS | -2.53 | -139.14 | -353.59 | -184.09 |
| % Growth | 98.2% | 60.6% | -92.1% | – |
| EPS Diluted | -2.53 | -138.65 | -353.59 | -184.09 |
| Weighted Avg Shares Out | 3,396 | 120 | 30 | 32 |
| Weighted Avg Shares Out Dil | 3,396 | 120 | 46 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $904 | $1,694 | $0 | $0 |
| Depreciation & Amortization | $381 | $356 | $483 | $119 |
| EBITDA | -$5,925 | -$4,095 | -$7,197 | -$8,743 |
| % Margin | -60.6% | -39.2% | -50% | -85.7% |